|
|
Article: Xenon reports scientific advancement in HDL-cholesterol program.
- Article from:
- Gene Therapy Weekly
- Article date:
- August 8, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 AUG 8 - (NewsRx.com & NewsRx.net) -- Xenon Genetics, Inc., announced that its research team, together with collaborators, have demonstrated that the gene (ABCA1) responsible for regulating levels of HDL cholesterol plays an important role in protecting against cardiovascular disease.
Xenon's research showed that mice over-expressing human ABCA1 had a marked reduction in atherosclerosis compared with mice where human ABCA1 was not over-expressed. These findings appeared in The Journal of Clinical Investigation.
Xenon's HDL program is based on the company's discovery of the ABCA1 gene as a major regulator of reverse cholesterol transport and HDL ...